White Paper - The Pharmaceutical Industry's Transition to Electronic Processes

Learn Why the FDA is Wanting the Pharmaceutical Industry to Transition to Electronic Systems and Processes

Download Now

	White Paper: The Pharmaceutical Industry's Transition to Electronic Processes

Watch Videos How MasterControl Makes Your Job Easier (3:50) A.P. Pharma (10:23) MasterControl's Documents Module (2:02)

Description: White Paper - The Pharmaceutical Industry?s Transition to Electronic Processes

A brief survey of the FDA’s efforts to encourage pharmaceutical companies to upgrade their paper-based or hybrid processes to modern, hi tech pharmaceutical processes that meet cGMP guidelines, and the many advantages of doing so, leaves little doubt that, indeed, this is where the industry as a whole is headed —despite the reluctance of many (especially small-to-midsized) pharmaceutical companies to abandon their traditional, largely paper-based, processes.

The urgency of the FDA to encourage the transition to hi tech pharmaceutical processes is understandable. Paper-based processes are notoriously unreliable, error-prone, and time-consuming. They slow the development of new medications, and dramatically increase costs—both directly and indirectly—for pharmaceutical companies, patients, and the government. So, why the hesitation on the part of many pharmaceutical companies to get with the program?  Are they just being obstinate?

Like most things, the situation is a little more complicated than it appears.  Also like most things, trying to understand where some pharmaceutical companies may be coming can be instructive—and it may help provide a solution.